{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:15:57Z","timestamp":1781532957313,"version":"3.54.5"},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AstraZeneca Deutschland GmbH\nDie AstraZeneca GmbH Hamburg hat diese Arbeit finanziell unterst\u00fctzt\nund die mit der Einreichung des Manuskripts verbundenen Geb\u00fchren\n\u00fcbernommen."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Beschreibung der Behandlungs- und Verordnungsmuster bei Asthma-Patient* innen in den KV-Bezirken Magdeburg (MD) und Mannheim (MA) im bundesweiten Vergleich.<\/jats:p>\n                  <jats:p>Wir analysierten IQVIA LRx-Daten im Zeitraum 7\/2022 bis 6\/2023. Die Verordnungsdatenbank LRx 1. Zur Zuordnung der Indikation Asthma bei Patient*innen mit \u2265 1 eingel\u00f6ster GKV-Verordnung f\u00fcr Atemwegserkrankungen wurde ein maschinelles Lernmodell genutzt.<\/jats:p>\n                  <jats:p>Es wurden 2992487 Patient*innen mit Asthma in Deutschland identifiziert (MD 20692; MA 55302), wovon 30 % der GINA-Stufe 4 (MD 33 %; MA 30 %) und 4 % der GINA-Stufe 5 (MD 5 %; MA 5 %) zugeordnet wurden (GINA: Global Initiative for Asthma 2). Nur 27 % wiesen \u2265 1 Verordnung von Pneumolog*innen auf (MD 37 %; MA 28 %). 13 % zeigten Anzeichen von Unkontrolliertheit (MD 12 %; MA 13 %). Von diesen waren 21 % potenziell f\u00fcr Biologika (Bx) geeignet (MD 22 %; MA 20 %), wovon 19 % \u2265 1 Biologika-Verordnung erhielten (MD 21 %; MA 22 %). Nur 11 % der Patient*innen mit unkontrolliertem Asthma hatten keine akuten orale Kortikosteroid (OCS)-Verordnungen (MD 10 %; MA 9 %). Von Patient*innen, die kontinuierlich mit Biologika behandelt wurden, wiesen 58 % (MD 68 %; MA 75 %) keine OCS-Verordnungen auf. Bundesweit wurden etwa 24% (MD 24 %; MA 31 %) dieser Patient*innen mit inhalativen Kortikosteroiden (ICS) in niedriger bis mittlerer Dosierung behandelt.<\/jats:p>\n                  <jats:p>Patient*innen mit schwerem Asthma oder Zeichen von Unkontrolliertheit ben\u00f6tigen eine zus\u00e4tzliche Versorgung durch Pneumolog*innen. Bei allen beobachteten regionalen Unterschieden in der Versorgung ist die Identifikation von Patient*innen mit unkontrolliertem Asthma und deren rasche \u00dcberweisung zu Pneumolog*innen ein wichtiger Ansatzpunkt zur Verbesserung. In der Versorgungsrealit\u00e4t hat eine Behandlung des schweren unkontrollierten Asthmas mit Biologika das Potenzial, den Einsatz oraler und inhalativer Kortikosteroide zu reduzieren.<\/jats:p>","DOI":"10.1055\/a-2748-4843","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T23:44:32Z","timestamp":1773445472000},"page":"e16-e22","source":"Crossref","is-referenced-by-count":0,"title":["Versorgung bei unkontrolliertem Asthma in Deutschland"],"prefix":"10.1055","volume":"151","author":[{"given":"Felix","family":"Herth","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Heidelberg (Thoraxklinik), Heidelberg, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Magdeburg, Magdeburg, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-7310","authenticated-orcid":false,"given":"Ingo","family":"Mokros","sequence":"additional","affiliation":[{"name":"AstraZeneca GmbH, Hamburg, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Claudius","family":"Schwitalla","sequence":"additional","affiliation":[{"name":"AstraZeneca GmbH, Hamburg, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Vetter","sequence":"additional","affiliation":[{"name":"IQVIA Commercial GmbH & Co.GmbH, Frankfurt, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5414\/CP204485","article-title":"German longitudinal prescription database (LRX): Description of characteristics, use in pharmacoepidemiological research, and limitations","volume":"62","author":"K Kostev","year":"2024","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"01","key":"ref5","first-page":"265","article-title":"Drivers of health care costs for adults with persistent asthma","volume":"6","author":"RS Zeiger","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaip.2015.08.003","article-title":"Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting","volume":"4","author":"RS Zeiger","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1080\/02770903.2022.2144350","article-title":"Epidemiology, treatment and health care resource use of patients with severe asthma in Germany \u2013 a retrospective claims data analysis","volume":"60","author":"F Hardtstock","year":"2023","journal-title":"J Asthma"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/02770903.2021.1878532","article-title":"German regional variation of acute and high oral corticosteroid use for asthma","volume":"59","author":"C Nan","year":"2022","journal-title":"Journal of Asthma"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2147\/JAA.S365967","article-title":"Prevalence of Patients with Uncontrolled Asthma Despite NVL\/GINA Step 4\/5 Treatment in Germany","volume":"15","author":"KC Bergmann","year":"2022","journal-title":"JAA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term OCS therapy and its side effects in severe asthma in adults \u2013 A focused review of the impact data in the literature","author":"T Volmer","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"04","key":"ref14","doi-asserted-by":"publisher","first-page":"00092","DOI":"10.1183\/23120541.00092-2019","article-title":"Prevalence of oral corticosteroid use in the German severe asthma population","volume":"5","author":"C Taube","year":"2019","journal-title":"ERJ Open Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106242","article-title":"Oral corticosteroid prescription for asthma by general practitioners: A three-year analysis in Germany","volume":"176","author":"M Lommatzsch","year":"2021","journal-title":"Respir Med"},{"issue":"S 63","key":"ref16","first-page":"PA2556","article-title":"Prevalence of the use of oral corticosteroids in asthma \u2013 a 3-year analysis in Germany","volume":"54","author":"M Lommatzsch","year":"2019","journal-title":"European Respiratory Journal [Internet]"},{"issue":"03","key":"ref17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management","volume":"201","author":"ER Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/all.13874","article-title":"Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden","volume":"74","author":"M Ekstr\u00f6m","year":"2019","journal-title":"Allergy"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"A Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"03","key":"ref20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/jcm12030985","article-title":"Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting","volume":"12","author":"C Vitale","year":"2023","journal-title":"Journal of Clinical Medicine"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2748-4843.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:50:05Z","timestamp":1781531405000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2748-4843"}},"subtitle":["mit Fokus auf die KV-Bezirke Magdeburg und Mannheim"],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":14,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2748-4843","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}